Silence Therapeutics Ord

7.4730+0.3230+4.52%Vol 6001Y Perf 33.57%
Dec 1st, 2021 12:31
BID0.0000 ASK0.0000
Open7.4730 Previous Close7.1500
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     41.01
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
48.64 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha0.05 Standard Deviation0.33
Beta1.09 

Today's Price Range

7.47307.4730

52W Range

5.79009.2500

5 Year PE Ratio Range

-11.400-15.900

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.74%
1 Month
9.57%
3 Months
-3.57%
6 Months
-19.21%
1 Year
33.57%
3 Years
522.75%
5 Years
-
10 Years
0.00%

TickerPriceChg.Chg.%
SLNCF7.47300.32304.52
AAPL163.76-1.0100-0.61
GOOG2 875.5343.17001.52
MSFT329.49-0.5900-0.18
XOM61.281.49002.49
WFC48.911.70003.60
JNJ157.09-0.9900-0.63
FB310.39-0.2100-0.07
GE95.232.23002.40
JPM161.213.32002.10
Financial StrengthValueIndustryS&P 500US Markets
4.20
4.50
-
0.01
2.81K
Leverage Ratio 5.70
ProfitabilityValueIndustryS&P 500US Markets
39.70
-421.50
-416.60
-
-
RevenueValueIndustryS&P 500US Markets
13.98M
0.16
-
-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume600
Shares Outstanding0
Shares Float89.78M
Trades Count1
Dollar Volume4.48K
Avg. Volume3.36K
Avg. Weekly Volume1.18K
Avg. Monthly Volume1.06K
Avg. Quarterly Volume1.11K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Silence Therapeutics Ord

Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Silence's technology is currently in the clinic in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.

CEO:

Telephone: +44 2034576900

Address: 72 Hammersmith Road, London W14 8TH, , GBR

Number of employees: 42

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

36%64%

Bearish Bullish

64%36%

News